First Allied Advisory Services’s Cascadian Therapeutics, Inc. CASC Stock Holding History

First Allied Advisory Services’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-3,333	Closed	-$33K	–	1198
2015 Q1	$33K	Hold	3,333	–	–	﹤0.01%	1055
2014 Q4	$38K	Hold	3,333	–	–	﹤0.01%	1013
2014 Q3	$38K	Hold	3,333	–	–	﹤0.01%	1016
2014 Q2	$65K	Sell	3,333 -84	-2%	-$1.48K	﹤0.01%	958
2014 Q1	$61K	Hold	3,417	–	–	﹤0.01%	978
2013 Q4	$36K	Buy	+3,417	New	+$38.2K	﹤0.01%	934
2013 Q3	–	Sell	-6,000	Closed	-$57K	–	1070
2013 Q2	$57K	Buy	+6,000	New	+$77.1K	﹤0.01%	927

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Allied Advisory Services's CASC Position: Q2 2015 in Review

First Allied Advisory Services sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2015, closing a stake of 3,333 shares — an estimated $33K sold.

First Allied Advisory Services first reported a position in CASC in Q2 2013 and held it in 7 quarters. The position peaked at $65K in Q2 2014. 100 funds tracked by Wall St. Rank hold CASC as of Q2 2015.

First Allied Advisory Services reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
First Allied Advisory Services sold 3,333 Cascadian Therapeutics, Inc. shares in Q2 2015, an estimated $33K.
First Allied Advisory Services first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 7 quarters.
First Allied Advisory Services's Cascadian Therapeutics, Inc. position peaked at $65K in Q2 2014.
100 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2015.

Based on First Allied Advisory Services's 13F filing for Q2 2015, filed 13 Aug 2015.